williams glp 1 Serena Opens Up About Using a GLP-1 to Support Weight Loss Postpartum Could Serena Williams' GLP-1 Disclosure

Heres What They Found Over 5 Years: Less opioid use : People taking GLP-1s were 40% less likely to use opioids

The peptide CDMO market, valued at approximately $4.14 billion in 2025, is forecast to reach $9.84 billion by 2031 at a compound annual growth rate of 15.5%

Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age 60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies

Is your protein intake adequate to protect muscle mass

Hales C, Carroll M, Fryar CD, et al

In clinical trials for weight management, tirzepatide produced average weight loss of 20-25% of body weight, roughly double what semaglutide achieves at comparable endpoints